Trial reportThe international journal of cardiovascular imaging2026
Overweight predisposes to microvascular obstruction: insights from the TATORT-NSTEMI trial.
Trial report in The international journal of cardiovascular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microvascular obstruction (MVO) is a phenomenon associated with worse outcome after acute myocardial infarction. While some studies suggested a benefit of an increased body mass index (BMI) in terms of MVO occurrence in ST-elevation myocardial infarction (STEMI), there are currently no data available on the influence of overweight on the development of MVO in Non-STEMI (NSTEMI). Thus, the aim of this study was to assess the association between MVO and BMI in NSTEMI patients. This study investigated a sub-cohort of the TATORT-NSTEMI trial. Overall, 354 patients were included with a median age of 68 years (25% women). Cardiac magnetic resonance imaging (CMR) was performed within four days after the index event. MVO was defined as hypointense core within the infarcted area in late-enhancement sequences. MVO occurred in 97 patients (27%) and patients with MVO had a significantly higher BMI (28.4 kg/m², interquartile range (IQR) 26.1-31.1 vs. 27.3 kg/m², IQR 24.8-30.3, p = 0.024). Dichotomized at 25.6 kg/m² (Youden-index), patients with a BMI above that threshold showed significantly more often MVO (33% vs. 15%, p < 0.001). In logistic regression analysis, BMI > 25.6 kg/m² was a significant predictor of MVO, independent of traditional cardiovascular risk factors. In the current study, an increased BMI has been associated with MVO after NSTEMI. Further, overweight and especially a BMI above 25.6 kg/m² were independent predictors of MVO in these patients, challenging the so-called "obesity paradox". Lastly, further research on the connection between body weight and microvascular damage in myocardial infarction is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.